Drug profile · INN
omaveloxolone
SKYCLARYS
omaveloxolone (SKYCLARYS) is a nuclear factor erythroid 2-related factor 2 activator. Route of administration: oral. Current US regulatory status: approved.
Drug details — omaveloxolone
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
omaveloxolone (SKYCLARYS) is a nuclear factor erythroid 2-related factor 2 activator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nuclear factor erythroid 2-related factor 2 activator
Primary target: Nuclear factor erythroid 2-related factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is omaveloxolone?
omaveloxolone (SKYCLARYS) is a nuclear factor erythroid 2-related factor 2 activator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for omaveloxolone?
SKYCLARYS is a marketed brand name for omaveloxolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omaveloxolone?
omaveloxolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.